Bristol Myers Squibb Company $BMY Shares Purchased by Waverly Advisors LLC

Waverly Advisors LLC lifted its stake in Bristol Myers Squibb Company (NYSE:BMY) by 306.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 349,560 shares of the biopharmaceutical company’s stock after acquiring an additional 263,590 shares during the period. Waverly Advisors LLC’s holdings in Bristol Myers Squibb were worth $20,142,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in BMY. California State Teachers Retirement System raised its holdings in Bristol Myers Squibb by 5,484.7% during the second quarter. California State Teachers Retirement System now owns 185,255,963 shares of the biopharmaceutical company’s stock worth $10,674,449,000 after purchasing an additional 181,938,762 shares in the last quarter. BlackRock Inc. boosted its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp increased its position in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after purchasing an additional 1,385,206 shares during the period. Geode Capital Management LLC raised its stake in shares of Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Bristol Myers Squibb in the 4th quarter worth $1,947,272,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Performance

BMY opened at $64.63 on Wednesday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The firm has a market cap of $132.02 billion, a PE ratio of 14.24, a P/E/G ratio of 0.32 and a beta of 0.23. The business has a fifty day simple moving average of $63.23 and a 200-day simple moving average of $60.00. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the firm earned $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BMY. Piper Sandler began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set an “overweight” rating for the company. JPMorgan Chase & Co. boosted their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Roth Capital began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price target for the company. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an “equal weight” rating in a research report on Friday, July 31st. Finally, Jefferies Financial Group cut shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Insider Buying and Selling

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.